Tominaga K, Saijo N, Eguchi K, Shinkai T, Shimizu E
Gan No Rinsho. 1984 Sep;30(11):1344-50.
A preliminary phase II study of cis-Dichlorodiammineplatinum (II) was carried out in 17 patients with non-small cell carcinoma (12 adenocarcinomas, 3 squamous cell carcinomas, 2 large cell carcinoma) of the lung, and in 15 patients with metastatic pulmonary tumor. All patients could be evaluated. A partial response was obtained in 2 of 12 adenocarcinoma patients and in 1 of 3 patients with squamous cell carcinoma, resulting in a partial response rate of 17.6%. A partial response was also obtained in one patient each from those with metastatic pulmonary tumor from the uterus, skin and pharynx and in patients with mediastinal tumor, resulting in a partial response rate of 26.7%. There was mild myelosuppression in our patients; renal toxicity and toxic neuropathy seemed to be the dose-limiting factors in cis-Dichlorodiammineplatinum (II) therapy.
对17例肺非小细胞癌（12例腺癌、3例鳞状细胞癌、2例大细胞癌）患者和15例转移性肺肿瘤患者进行了顺式二氯二氨铂（II）的II期初步研究。所有患者均可进行评估。12例腺癌患者中有2例、3例鳞状细胞癌患者中有1例获得部分缓解，部分缓解率为17.6%。子宫、皮肤和咽部转移性肺肿瘤患者以及纵隔肿瘤患者中各有1例获得部分缓解，部分缓解率为26.7%。我们的患者有轻度骨髓抑制；肾毒性和毒性神经病变似乎是顺式二氯二氨铂（II）治疗的剂量限制因素。
